<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet title="XSL_formatting" type="text/xsl" href="/~/media/Files/S/staar-surgical/XSL/rss_xsl.xsl"?> 
<rss version="2.0" xmlns:dt="http://xsltsl.org/date-time">
 <channel>
  <title>RSS - Staar Surgical - Press Releases </title>
  <link>https://investors.staar.com/rss/press-releases</link>
  <language>en</language>
<webMaster>Staar Surgical</webMaster>
<image>
<url>https://investors.staar.com/~/media/Images/S/staar-surgical/logo/logo-dark.svg</url>
</image>
<item>
<title><![CDATA[STAAR Surgical Issues Shareholder Letter]]></title>
<description><![CDATA[STAAR Surgical Company, the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses for vision correction, today issued a Shareholder Letter on Tuesday, March 3 after the market close. STAAR’ s results release can be found here: https://investors.staar.com/news-and-events/press-releases. This past month marked an important...]]></description>
<link>https://investors.staar.com/news-and-events/press-releases/2026/03-03-2026-210206703</link>
<pubDate>Tue, 03 Mar 2026 20:02:00 GMT</pubDate>
<publishDate>Tue, 03 Mar 2026 21:07:47 GMT</publishDate>
<guid>{8D0A7F09-1483-4CF6-B1C0-12CC67C5B40A}</guid>
<isalertable>False</isalertable>
</item>
<item>
<title><![CDATA[STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results]]></title>
<description><![CDATA[Net sales of $57.8 million, up 18.1% Y/Y Net sales excluding China of $40.3 million, down 2.1% Y/Y Gross margin at 75.7% vs. 64.7% Y/Y Net loss of$ million or$ per share, compared to a net loss of$ million or$ per share a year ago Adjusted EBITDA 1 breakeven or$ per share, compared to Adjusted EBITDA loss of$ million or$ per share a year ago. Net sales of $239.4 million, down 23.7%...]]></description>
<link>https://investors.staar.com/news-and-events/press-releases/2026/03-03-2026-210122574</link>
<pubDate>Tue, 03 Mar 2026 20:01:00 GMT</pubDate>
<publishDate>Tue, 03 Mar 2026 21:07:47 GMT</publishDate>
<guid>{C4B511CF-76CE-486D-B296-BB90810A7BB3}</guid>
<isalertable>False</isalertable>
</item>
<item>
<title><![CDATA[STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction]]></title>
<description><![CDATA[STAAR Surgical Company, the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses for vision correction, today announced that more than 4 million Implantable Collamer ® Lenses have been sold worldwide, marking a milestone in the global shift away from laser-based refractive surgery. This achievement underscores the growing...]]></description>
<link>https://investors.staar.com/news-and-events/press-releases/2026/02-25-2026-210120911</link>
<pubDate>Wed, 25 Feb 2026 20:01:00 GMT</pubDate>
<publishDate>Wed, 25 Feb 2026 21:01:23 GMT</publishDate>
<guid>{94899A5D-1ED8-4CE3-91AB-25ED7E1FC02E}</guid>
<isalertable>False</isalertable>
</item>
<item>
<title><![CDATA[STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026]]></title>
<description><![CDATA[STAAR Surgical Company, the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m....]]></description>
<link>https://investors.staar.com/news-and-events/press-releases/2026/02-23-2026-210109746</link>
<pubDate>Mon, 23 Feb 2026 20:01:00 GMT</pubDate>
<publishDate>Mon, 23 Feb 2026 21:01:11 GMT</publishDate>
<guid>{EA51C41F-48BA-4052-BD91-E9B6B1512463}</guid>
<isalertable>False</isalertable>
</item>
<item>
<title><![CDATA[FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction]]></title>
<description><![CDATA[STAAR Surgical Company, the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses for vision correction, today announced that the U.S. Food and Drug Administration has approved an expanded age indication for EVO/EVO+ Visian ® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after...]]></description>
<link>https://investors.staar.com/news-and-events/press-releases/2026/02-17-2026-210124036</link>
<pubDate>Tue, 17 Feb 2026 20:01:00 GMT</pubDate>
<publishDate>Tue, 17 Feb 2026 21:01:24 GMT</publishDate>
<guid>{A3822D26-913D-47FC-BB1C-E18ABD4DDA44}</guid>
<isalertable>False</isalertable>
</item>
<item>
<title><![CDATA[STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs]]></title>
<description><![CDATA[STAAR Surgical Company, the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses for vision correction, today announced that its Board of Directors has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026.]]></description>
<link>https://investors.staar.com/news-and-events/press-releases/2026/02-02-2026-120102805</link>
<pubDate>Mon, 02 Feb 2026 11:00:00 GMT</pubDate>
<publishDate>Mon, 02 Feb 2026 12:01:05 GMT</publishDate>
<guid>{6FA7603A-622C-4853-BE1C-137B9D97B30C}</guid>
<isalertable>False</isalertable>
</item>
<item>
<title><![CDATA[STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement]]></title>
<description><![CDATA[STAAR Surgical Company, the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses for vision correction, and Broadwood Partners, L.P. and its affiliates, which together own 31% of STAAR’ s outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with...]]></description>
<link>https://investors.staar.com/news-and-events/press-releases/2026/01-15-2026-133045807</link>
<pubDate>Thu, 15 Jan 2026 12:30:00 GMT</pubDate>
<publishDate>Thu, 15 Jan 2026 13:30:46 GMT</publishDate>
<guid>{3371693B-F56E-4FCC-8112-6043A049F39B}</guid>
<isalertable>False</isalertable>
</item>
<item>
<title><![CDATA[STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders]]></title>
<description><![CDATA[STAAR Surgical Company, the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses for vision correction, announced that based on preliminary estimates by STAAR’ s proxy solicitor, STAAR did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held today.]]></description>
<link>https://investors.staar.com/news-and-events/press-releases/2026/01-06-2026-134720114</link>
<pubDate>Tue, 06 Jan 2026 12:47:00 GMT</pubDate>
<publishDate>Tue, 06 Jan 2026 13:47:21 GMT</publishDate>
<guid>{21CB58EF-E599-4B83-80C0-CEF06F10960D}</guid>
<isalertable>False</isalertable>
</item>
<item>
<title><![CDATA[Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders]]></title>
<description><![CDATA[STAAR Surgical Company, the manufacturer of the Implantable Collamer ® Lens today announced that Alcon has exercised its right under the Alcon merger agreement to require STAAR to adjourn its Special Meeting of Stockholders in connection with the Alcon merger agreement. As a result, the Special Meeting, which was scheduled for December 19, 2025 at...]]></description>
<link>https://investors.staar.com/news-and-events/press-releases/2025/12-19-2025-164506909</link>
<pubDate>Fri, 19 Dec 2025 15:45:00 GMT</pubDate>
<publishDate>Fri, 19 Dec 2025 16:50:11 GMT</publishDate>
<guid>{5473FFA1-26BB-4F6D-922B-90E5AA5B4172}</guid>
<isalertable>False</isalertable>
</item>
<item>
<title><![CDATA[STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value]]></title>
<description><![CDATA[STAAR Surgical Company, the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses for vision correction, today issued the following open letter to STAAR stockholders:. The Special Meeting of Stockholders to vote on the amended agreement with Alcon Inc. is just days away. Vote to approve the Alcon agreement and receive the $30.75 per...]]></description>
<link>https://investors.staar.com/news-and-events/press-releases/2025/12-17-2025-155516264</link>
<pubDate>Wed, 17 Dec 2025 14:55:00 GMT</pubDate>
<publishDate>Wed, 17 Dec 2025 15:55:18 GMT</publishDate>
<guid>{F0193ED2-1061-4166-90CC-EDE74BB107C6}</guid>
<isalertable>False</isalertable>
</item>

  
 </channel>
</rss>